The study demonstrated for the first time the existence of an IKZF1-CRLF2 pathway in high-risk ALL and suggested that targeting this pathway could be used as a therapeutic approach for high-risk B-ALL. The gene discussed is CRLF2; the disease is acute lymphoblastic leukemia.